LIVIVO - Search results -

Search results

Result 1 - 10 of total 15

Search options

Article ; Online: Altered Tryptophan Levels in Patients With Inflammatory Bowel Disease Owing to Colonic Leakage, Metabolism, or Malabsorption?

Bosch, Sofie / de Meij, Tim G J / de Boer, Nanne Kh

2018 Volume 154, Issue 6, Page(s) 1855–1856

MeSH term(s)	Colon ; Humans ; Inflammatory Bowel Diseases ; Malabsorption Syndromes ; Tryptophan
Chemical Substances	Tryptophan (8DUH1N11BX)
Language	English
Publishing date	2018
Publishing country	United States
Document type	Letter ; Comment
ZDB-ID	80112-4
ISSN	1528-0012 ; 0016-5085
ISSN (online)	1528-0012
ISSN	0016-5085
DOI	10.1053/j.gastro.2018.01.071
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui V Zs.44: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 572: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Endoscopic and surgical treatment outcomes of colitis-associated advanced colorectal neoplasia: a multicenter cohort study.

Derks, Monica Ew / Te Groen, Maarten / Peters, Charlotte P / Dijkstra, Gerard / de Vries, Annemarie C / Romkens, Tessa Eh / Horjus, Carmen S / de Boer, Nanne Kh / Bemelman, Willem A / Nagtegaal, Iris D / Derikx, Lauranne Aap / Hoentjen, Frank

International journal of surgery (London, England)

2023 Volume 109, Issue 7, Page(s) 1961–1969

Abstract: Background: Inflammatory bowel disease (IBD) patients are at increased risk of advanced neoplasia (high-grade dysplasia or colorectal cancer). The authors aimed to (1) assess synchronous and metachronous neoplasia following (sub)total or proctocolectomy, ...

Abstract	Background: Inflammatory bowel disease (IBD) patients are at increased risk of advanced neoplasia (high-grade dysplasia or colorectal cancer). The authors aimed to (1) assess synchronous and metachronous neoplasia following (sub)total or proctocolectomy, partial colectomy or endoscopic resection for advanced neoplasia in IBD, and (2) identify factors associated with treatment choice. Material and methods: In this retrospective multicenter cohort study, the authors used the Dutch nationwide pathology databank (PALGA) to identify patients diagnosed with IBD and colonic advanced neoplasia (AN) between 1991 and 2020 in seven hospitals in the Netherlands. Logistic and Fine & Gray's subdistribution hazard models were used to assess adjusted subdistribution hazard ratios for metachronous neoplasia and associations with treatment choice. Results: The authors included 189 patients (high-grade dysplasia n =81; colorectal cancer n =108). Patients were treated with proctocolectomy ( n =33), (sub)total colectomy ( n =45), partial colectomy ( n =56) and endoscopic resection ( n =38). Partial colectomy was more frequently performed in patients with limited disease and older age, with similar patient characteristics between Crohn's disease and ulcerative colitis. Synchronous neoplasia was found in 43 patients (25.0%; (sub)total or proctocolectomy n =22, partial colectomy n =8, endoscopic resection n =13). The authors found a metachronous neoplasia rate of 6.1, 11.5 and 13.7 per 100 patient-years after (sub)total colectomy, partial colectomy and endoscopic resection, respectively. Endoscopic resection, but not partial colectomy, was associated with an increased metachronous neoplasia risk (adjusted subdistribution hazard ratios 4.16, 95% CI 1.64-10.54, P <0.01) compared with (sub)total colectomy. Conclusion: After confounder adjustment, partial colectomy yielded a similar metachronous neoplasia risk compared to (sub)total colectomy. High metachronous neoplasia rates after endoscopic resection underline the importance of strict subsequent endoscopic surveillance.
MeSH term(s)	Humans ; Cohort Studies ; Colonoscopy ; Colorectal Neoplasms/pathology ; Colitis/etiology ; Colitis/pathology ; Colitis/surgery ; Colitis, Ulcerative/surgery ; Inflammatory Bowel Diseases/complications ; Inflammatory Bowel Diseases/pathology ; Inflammatory Bowel Diseases/surgery ; Colonic Neoplasms/surgery ; Colectomy/adverse effects ; Treatment Outcome ; Retrospective Studies
Language	English
Publishing date	2023-07-01
Publishing country	United States
Document type	Multicenter Study ; Journal Article
ZDB-ID	2212038-5
ISSN	1743-9159 ; 1743-9191
ISSN (online)	1743-9159
ISSN	1743-9191
DOI	10.1097/JS9.0000000000000335
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6502: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma.

Bosch, Sofie / Acharjee, Animesh / Quraishi, Mohammed N / Rojas, Patricia / Bakkali, Abdellatif / Jansen, Erwin Ew / Brizzio Brentar, Marina / Kuijvenhoven, Johan / Stokkers, Pieter / Struys, Eduard / Beggs, Andrew D / Gkoutos, Georgios V / de Meij, Tim Gj / de Boer, Nanne Kh

Gut microbes

2022 Volume 14, Issue 1, Page(s) 2038863

Abstract: The risk of recurrent dysplastic colonic lesions is increased following polypectomy. Yield of endoscopic surveillance after adenoma removal is low, while interval colorectal cancers occur. To longitudinally assess the dynamics of fecal microbiota and ... ...

Abstract	The risk of recurrent dysplastic colonic lesions is increased following polypectomy. Yield of endoscopic surveillance after adenoma removal is low, while interval colorectal cancers occur. To longitudinally assess the dynamics of fecal microbiota and amino acids in the presence of adenomatous lesions and after their endoscopic removal. In this longitudinal case-control study, patients collected fecal samples prior to bowel preparation before scheduled colonoscopy and 3 months after this intervention. Based on colonoscopy outcomes, patients with advanced adenomas and nonadvanced adenomas (0.5-1.0 cm) who underwent polypectomy during endoscopy (
MeSH term(s)	Adenoma/diagnosis ; Adenoma/pathology ; Amino Acids ; Case-Control Studies ; Colorectal Neoplasms/pathology ; Gastrointestinal Microbiome ; Humans ; Risk Factors
Chemical Substances	Amino Acids
Language	English
Publishing date	2022-02-18
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ISSN	1949-0984
ISSN (online)	1949-0984
DOI	10.1080/19490976.2022.2038863
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Integration of stool microbiota, proteome and amino acid profiles to discriminate patients with adenomas and colorectal cancer.

Bosch, Sofie / Acharjee, Animesh / Quraishi, Mohammed Nabil / Bijnsdorp, Irene V / Rojas, Patricia / Bakkali, Abdellatif / Jansen, Erwin Ew / Stokkers, Pieter / Kuijvenhoven, Johan / Pham, Thang V / Beggs, Andrew D / Jimenez, Connie R / Struys, Eduard A / Gkoutos, Georgios V / de Meij, Tim Gj / de Boer, Nanne Kh

Gut microbes

2022 Volume 14, Issue 1, Page(s) 2139979

Abstract: Background: Screening for colorectal cancer (CRC) reduces its mortality but has limited sensitivity and specificity. Aims We aimed to explore potential biomarker panels for CRC and adenoma detection and to gain insight into the interaction between gut ... ...

Abstract	Background: Screening for colorectal cancer (CRC) reduces its mortality but has limited sensitivity and specificity. Aims We aimed to explore potential biomarker panels for CRC and adenoma detection and to gain insight into the interaction between gut microbiota and human metabolism in the presence of these lesions. Methods: This multicenter case-control cohort was performed between February 2016 and November 2019. Consecutive patients ≥18 years with a scheduled colonoscopy were asked to participate and divided into three age, gender, body-mass index and smoking status-matched subgroups: CRC (n = 12), adenomas (n = 21) and controls (n = 20). Participants collected fecal samples prior to bowel preparation on which proteome (LC-MS/MS), microbiota (16S rRNA profiling) and amino acid (HPLC) composition were assessed. Best predictive markers were combined to create diagnostic biomarker panels. Pearson correlation-based analysis on selected markers was performed to create networks of all platforms. Results: Combining omics platforms provided new panels which outperformed hemoglobin in this cohort, currently used for screening (AUC 0.98, 0.95 and 0.87 for CRC vs controls, adenoma vs controls and CRC vs adenoma, respectively). Integration of data sets revealed markers associated with increased blood excretion, stress- and inflammatory responses and pointed toward downregulation of epithelial integrity. Conclusions: Integrating fecal microbiota, proteome and amino acids platforms provides for new biomarker panels that may improve noninvasive screening for adenomas and CRC, and may subsequently lead to lower incidence and mortality of colon cancer.
MeSH term(s)	Humans ; Proteome/analysis ; Colorectal Neoplasms/diagnosis ; Colorectal Neoplasms/genetics ; Chromatography, Liquid ; RNA, Ribosomal, 16S ; Amino Acids ; Gastrointestinal Microbiome ; Tandem Mass Spectrometry ; Adenoma/diagnosis ; Feces/chemistry
Chemical Substances	Proteome ; RNA, Ribosomal, 16S ; Amino Acids
Language	English
Publishing date	2022-11-11
Publishing country	United States
Document type	Multicenter Study ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2575755-6
ISSN	1949-0984 ; 1949-0984
ISSN (online)	1949-0984
ISSN	1949-0984
DOI	10.1080/19490976.2022.2139979
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Golimumab for the treatment of ulcerative colitis.

Löwenberg, Mark / de Boer, Nanne Kh / Hoentjen, Frank

Clinical and experimental gastroenterology

2014 Volume 7, Page(s) 53–59

Abstract: The introduction of therapeutic antibodies against tumor necrosis factor (TNF) had a major impact on the treatment of ulcerative colitis (UC). Infliximab and adalimumab are powerful agents that are used for remission induction and maintenance therapy in ... ...

Abstract	The introduction of therapeutic antibodies against tumor necrosis factor (TNF) had a major impact on the treatment of ulcerative colitis (UC). Infliximab and adalimumab are powerful agents that are used for remission induction and maintenance therapy in UC and have an acceptable safety profile. However, a proportion of UC patients for whom therapy with anti-TNF agents is indicated fail or become intolerant to treatment with infliximab or adalimumab. Hence, there remains an unmet need for novel anti-TNF agents. Golimumab (Simponi®), a human anti-TNF antibody that is administered by monthly subcutaneous injections, is the most recently introduced TNF blocker for the treatment of UC. Here, we will discuss recent literature on clinical efficacy and safety of golimumab induction and maintenance treatment in patients with UC. Furthermore, we will discuss the positioning of golimumab for UC in current treatment algorithms.
Language	English
Publishing date	2014-03-12
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	2520690-4
ISSN	1178-7023
ISSN	1178-7023
DOI	10.2147/CEG.S48741
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Management of Crohn's disease in poor responders to adalimumab.

de Boer, Nanne Kh / Löwenberg, Mark / Hoentjen, Frank

Clinical and experimental gastroenterology

2014 Volume 7, Page(s) 83–92

Abstract: Anti-tumor necrosis factor therapy with adalimumab is an effective therapy for the induction and maintenance of remission in moderate to severe Crohn's disease. Although a large proportion of patients show a favorable clinical response to adalimumab, ... ...

Abstract	Anti-tumor necrosis factor therapy with adalimumab is an effective therapy for the induction and maintenance of remission in moderate to severe Crohn's disease. Although a large proportion of patients show a favorable clinical response to adalimumab, therapy failure is common. In this review, we provide a practical overview of adalimumab therapy in patients with Crohn's disease, with a specific focus on the clinical management of adalimumab failure. In the case of inadequate efficacy, a thorough assessment is required to confirm inflammatory disease activity and rule out noninflammatory causes. Evaluation may include biomarkers (fecal calprotectin and serum C-reactive protein), colonoscopy, and/or magnetic resonance enterography/enteroclysis. Furthermore, adalimumab trough levels and antibodies to adalimumab are informational after the confirmation of active inflammation. In the case of low or undetectable adalimumab trough levels, dose escalation to 40 mg weekly is recommended, whereas high antibody titers or adverse events frequently require switching to an alternative anti-TNF agent such as infliximab. Active inflammation despite therapeutic adalimumab trough levels requires alternative strategies such as switching to drugs with a different mode of action or surgical intervention.
Language	English
Publishing date	2014-04-11
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	2520690-4
ISSN	1178-7023
ISSN	1178-7023
DOI	10.2147/CEG.S47627
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review.

Meijer, Berrie / Mulder, Chris Jj / Peters, Godefridus J / van Bodegraven, Adriaan A / de Boer, Nanne Kh

World journal of gastroenterology

2016 Volume 22, Issue 40, Page(s) 9012–9021

Abstract: Aim: To critically assess the available literature regarding the efficacy of thioguanine treatment in inflammatory bowel disease (IBD) patients, irrespective of the (hepato-) toxicity profile.: Methods: A systematic literature search of the MEDLINE ... ...

Abstract	Aim: To critically assess the available literature regarding the efficacy of thioguanine treatment in inflammatory bowel disease (IBD) patients, irrespective of the (hepato-) toxicity profile. Methods: A systematic literature search of the MEDLINE database using PubMed was performed using the keywords "thioguanine", "6-TG", "thioguanine", "inflammatory bowel disease", "IBD", "Crohn's disease", "Ulcerative colitis" and "effectiveness" in order to identify relevant articles published in English starting from 2000. Reference lists of the included articles were cross-checked for missing articles. Reviewed manuscripts concerning the effectiveness of thioguanine treatment in IBD were reviewed by the authors and the data were extracted. Data were subsequently analyzed with descriptive statistics. Due to the lack of standardized outcomes, a formal meta-analysis was not performed. Results: A total of 11 applicable studies were found that involved the effectiveness of thioguanine therapy in IBD. Eight studies were conducted in a prospective manner, in the remaining three studies, data was collected retrospectively. In total, 353 IBD-patients (225 patients with Crohn's disease, 119 with ulcerative colitis and nine with unclassified IBD) with prior azathioprine/mercaptopurine resistance and/or intolerance ( Conclusion: The efficacy of thioguanine therapy in IBD patients intolerant to conventional thiopurine therapy is observed in 65%, with short term adverse events in 20% of patients.
MeSH term(s)	Antimetabolites, Antineoplastic/therapeutic use ; Humans ; Inflammatory Bowel Diseases/drug therapy ; Thioguanine/therapeutic use
Chemical Substances	Antimetabolites, Antineoplastic ; Thioguanine (FTK8U1GZNX)
Language	English
Publishing date	2016-10-28
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2185929-2
ISSN	2219-2840 ; 1007-9327
ISSN (online)	2219-2840
ISSN	1007-9327
DOI	10.3748/wjg.v22.i40.9012
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6039: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: The influence of lifestyle factors on fecal volatile organic compound composition as measured by an electronic nose.

Bosch, Sofie / Lemmen, Jesse Pm / Menezes, Renée / van der Hulst, René / Kuijvenhoven, Johan / Stokkers, Pieter Cf / de Meij, Tim Gj / de Boer, Nanne Kh

Journal of breath research

2019 Volume 13, Issue 4, Page(s) 46001

Abstract: Introduction: Fecal volatile organic compounds (VOCs) are gaseous metabolic products which are increasingly considered potential non-invasive biomarkers for the detection of various (gastrointestinal) diseases. The influence of lifestyle factors on ... ...

Abstract	Introduction: Fecal volatile organic compounds (VOCs) are gaseous metabolic products which are increasingly considered potential non-invasive biomarkers for the detection of various (gastrointestinal) diseases. The influence of lifestyle factors on fecal VOC patterns remains unexplored but is of importance prior to implementation of VOC analysis as a diagnostic tool. The aim of this study was to investigate the effects of age, gender, body mass index, smoking status, dietary preferences, medication use and co-morbidity on fecal VOC patterns. Methods: For this study, fecal samples of patients undergoing a colonoscopy were collected prior to endoscopy. All participants completed a questionnaire on lifestyle factors, co-morbidity and medication use. Patients without colonic abnormalities were included in this study. Fecal VOC patterns were analyzed by means of an electronic nose (eNose) device (Cyranose Results: From the 1039 participants willing to participate in the initial study, 211 were eligible as controls. All unique lifestyle variables investigated in this study affected the fecal VOC composition. The strongest influences were caused by low BMI, a vegetarian diet and an active smoking status, whereas the least influence was found for the variables gender, age > 55 years and previous smokers. Discussion: Age, gender, BMI, smoking habits, dietary preferences, co-morbidity and medication use all have unique effects on fecal VOC composition. Future studies should carefully consider this influence on VOC outcome when defining VOC signatures as biomarker for diagnostic purposes.
MeSH term(s)	Adolescent ; Adult ; Aged ; Aged, 80 and over ; Breath Tests ; Electronic Nose ; Factor Analysis, Statistical ; Feces/chemistry ; Female ; Humans ; Life Style ; Male ; Middle Aged ; Volatile Organic Compounds/analysis ; Young Adult
Chemical Substances	Volatile Organic Compounds
Language	English
Publishing date	2019-06-25
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2381007-5
ISSN	1752-7163 ; 1752-7155
ISSN (online)	1752-7163
ISSN	1752-7155
DOI	10.1088/1752-7163/ab2775
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: High inter-individual variability of serum xanthine oxidoreductase activity in IBD patients.

Meijer, Berrie / Seinen, Margien L / Hosman, Tessa / Linskens, Ronald K / Kneppelhout, Jan-Kees / Peters, Godefridus J / Mulder, Chris Jj / van Bodegraven, Adriaan A / de Boer, Nanne Kh

Nucleosides, nucleotides & nucleic acids

2018 Volume 37, Issue 6, Page(s) 317–323

Abstract: Objectives: Thiopurines play an essential role in the management of inflammatory bowel diseases (IBD, i.e. Crohn's disease and ulcerative colitis). Over the past decade, several strategies to optimize treatment with thiopurines have been evaluated, ... ...

Abstract	Objectives: Thiopurines play an essential role in the management of inflammatory bowel diseases (IBD, i.e. Crohn's disease and ulcerative colitis). Over the past decade, several strategies to optimize treatment with thiopurines have been evaluated, including co-administration of allopurinol, a xanthine-oxidoreductase (XO) inhibitor, to low-dose thiopurine therapy. We aimed to assess the inter-individual variability of XO-activity between IBD-patients. Methods: We assessed XO activity in serum of IBD-patients of two medical centers in The Netherlands using the Amplex® Red Xanthine/Xanthine Oxidase Assay Kit, which measures the superoxide formation in a coupled reaction to the red-fluorescent oxidation product, resofurine. Results: We observed a high inter-individual variability of XO-activity in 119 patients, with a median activity of 16 µU/ml/hour (range 1-85 µU/ml/hour). The XO-activity was influenced by gender (male 19.5 vs. female 14.0 µU/ml/hour, p < 0.01), patient's age (Pearson's correlation r = 0.21, p = 0.02) and duration of IBD (r = 0.23, p = 0.01). The XO activity was not affected by the type of IBD, smoking status, body mass index or (type of) thiopurine use (p > 0.05). Conclusions: There is a high inter-individual variability of XO-activity in IBD-patients; XO-activity is positively associated with male gender and patient's age.
MeSH term(s)	Adult ; Age Factors ; Aged ; Aged, 80 and over ; Cross-Sectional Studies ; Female ; Humans ; Inflammatory Bowel Diseases/blood ; Male ; Middle Aged ; Retrospective Studies ; Sex Factors ; Signal Transduction ; Xanthine Dehydrogenase/blood ; Young Adult
Chemical Substances	Xanthine Dehydrogenase (EC 1.17.1.4)
Language	English
Publishing date	2018-05-03
Publishing country	United States
Document type	Journal Article ; Multicenter Study
ZDB-ID	2008956-9
ISSN	1532-2335 ; 1525-7770
ISSN (online)	1532-2335
ISSN	1525-7770
DOI	10.1080/15257770.2018.1460477
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3870: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Diarrhoea in a patient with metastatic melanoma: Ipilimumab ileocolitis treated with infliximab.

Slangen, Rob Me / van den Eertwegh, Alfonsus Jm / van Bodegraven, Adriaan A / de Boer, Nanne Kh

World journal of gastrointestinal pharmacology and therapeutics

2013 Volume 4, Issue 3, Page(s) 80–82

Abstract: Administration of ipilimumab, a cytotoxic T-lymphocyte associated antigen-4-blocking monoclonal antibody, leads to enhancement of the anti-tumor T-cell respons and as a result shows a significant survival benefit in metastatic melanoma patients. ... ...

Abstract	Administration of ipilimumab, a cytotoxic T-lymphocyte associated antigen-4-blocking monoclonal antibody, leads to enhancement of the anti-tumor T-cell respons and as a result shows a significant survival benefit in metastatic melanoma patients. Therefore patients are currently receiving this promising therapy as a second-line strategy. Unfortunately, by activation of the T-cell immune response, ipilimumab therapy may lead to an unwanted induction of different autoimmune phenomena. Diarrhoea and colitis occur in up to one third of patients. Here we present a case of ipilimumab induced ileocolitis which was successfully treated with infliximab, an anti-tumor necrosis factor monoclonal antibody, after corticosteroid therapy failure. Although formal trials are lacking, recently publicated series suggest that infusional therapy of infliximab is effective in ipilimumab induced ileocolitis.
Language	English
Publishing date	2013-06-14
Publishing country	United States
Document type	Journal Article
ZDB-ID	2583480-0
ISSN	2150-5349
ISSN	2150-5349
DOI	10.4292/wjgpt.v4.i3.80
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito